Cosmo reported record preliminary 2022 results with key drivers such as Winlevi off to a solid start in the US. Legacy products such as Lialda, and Uceris/Cortiment added to the record revenues. Cosmo is one of the few profitable SIX-listed biopharma companies with sufficient cash to fund its development plans and pay dividends.
Key catalysts include:
1. Start phase III trial Breezula in male alopecia (Q1 2023)
2. Winlevi licensing agreements (2023)
3. Winlevi filing for EU approval (H2 2023)